Nivolumab-Induced Secondary Sclerosing Cholangitis with Deterioration Despite Immunosuppression

被引：15
作者：
Anderson, Brady [1 ]
Dawe, David E. [1 ,2 ]
机构：
[1] Univ Manitoba, Dept Internal Med, Winnipeg, MB, Canada
[2] CancerCare Manitoba, Dept Med Oncol & Hematol, Winnipeg, MB, Canada
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 09期
关键词：
D O I：
10.1016/j.jtho.2019.04.023
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E205 / E206
页数：3
相关论文
共 5 条
  • [1] Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury
    Gelsomino, F.
    Vitale, G.
    D'Errico, A.
    Bertuzzi, C.
    Andreone, P.
    Ardizzoni, A.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 (03) : 671 - 672
  • [2] Pembrolizumab for the treatment of thoracic malignancies: current landscape and future directions
    Karim, Safiya
    Leighl, Natasha
    [J]. FUTURE ONCOLOGY, 2016, 12 (01) : 9 - 23
  • [3] Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer
    Kawakami, Hisato
    Tanizaki, Junko
    Tanaka, Kaoru
    Haratani, Koji
    Hayashi, Hidetoshi
    Takeda, Masayuki
    Kamata, Ken
    Takenaka, Mamoru
    Kimura, Masatomo
    Chikugo, Takaaki
    Sato, Takao
    Kudo, Masatoshi
    Ito, Akihiko
    Nakagawa, Kazuhiko
    [J]. INVESTIGATIONAL NEW DRUGS, 2017, 35 (04) : 529 - 536
  • [4] Poor response of initial steroid therapy for IgG4-related sclerosing cholangitis with multiple organs affected
    Liu, Wei
    Chen, Weijie
    He, Xiaodong
    Qu, Qiang
    Hong, Tao
    Li, Binglu
    [J]. MEDICINE, 2017, 96 (12)
  • [5] Primary Sclerosing Cholangitis: Diagnosis, Prognosis, and Management
    Singh, Siddharth
    Talwalkar, Jayant A.
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2013, 11 (08) : 898 - 907
1